8-K: Current report
8-K: Current report
8-K/A: Current report (Amendment)
8-K: eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
8-K: Current report
DEFA14A: Others
DEF 14A: Definitive information statements
PRE 14A: Preliminary proxy statements relating to merger or acquisition
eFFECTOR Therapeutics | 8-K: Current report
eFFECTOR Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
eFFECTOR Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
eFFECTOR Therapeutics | 8-K: eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
eFFECTOR Therapeutics | 8-K: Current report
eFFECTOR Therapeutics | 8-K: Current report
eFFECTOR Therapeutics | 8-K: Current report
eFFECTOR Therapeutics | 8-K: Current report
eFFECTOR Therapeutics | 8-K: Current report
eFFECTOR Therapeutics | 8-K: Current report
eFFECTOR Therapeutics | 8-K: eFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
eFFECTOR Therapeutics | 8-K: Current report
No Data